The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in patients aged 12 and older who remain symptomatic despite antihistamine treatment ...

The most common adverse reaction reported with dupilumab in all 3 CUPID trials were injection site reactions. “Dupixent is the first new targeted treatment for chronic spontaneous urticaria ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

Dupixent is an injection administered under the skin ... professional and can be given in a clinic or at home after training by a healthcare professional. In adolescents aged 12 to 17 years ...

About Dupixent Dupixent (dupilumab) is an injection administered under the ... and can be given in a clinic or at home after training by a healthcare professional. In adolescents aged 12 to ...

In pooled data from all three studies, the most common adverse event (≥2%) more frequently observed in patients on Dupixent compared to placebo was injection site reactions.